Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CPB1 | P15086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15485863 | 1.00 | GABRR1 (0.32) | GABRR1LMNASLC22A6TDP1SMN1; SMN2 | |
| SCHEMBL27150907 | 1.00 | GABRR1 (0.32) | GABRR1LMNASLC22A6TDP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23780646 | 0.98 | GABRR1 (0.31) | GABRR1LMNASLC22A6TDP1 | |
| Hydrochloric Acid SCHEMBL23924127 | 0.98 | GABRR1 (0.31) | GABRR1LMNASLC22A6TDP1 | |
| SCHEMBL28501491 | 0.77 | — | — | |
| SCHEMBL15525400 | 0.74 | — | — | |
| SCHEMBL13482801 | 0.74 | — | — | |
| SCHEMBL13539959 | 0.74 | — | — | |
| SCHEMBL22256378 | 0.73 | CYP2D6 (0.35) | — | |
| SCHEMBL13786827 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790202-B | Cyclic peptide, affinity chromatography carrier, labeled antibody, antibody drug complex and pharmaceutical preparation | 富士胶片株式会社 | 2022-09-13 | — | — | CN | claimed |
| WO-2022104001-A1 | EXPANDED PROTEIN LIBRARIES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-19 | — | — | WO | claimed |
| US-20200237924-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | KINETA CHRONIC PAIN, LLC (US) | 2020-07-30 | — | — | US | claimed |
| US-20250049943-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2025-02-13 | — | — | US | disclosed |
| US-20240398972-A1 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2024-12-05 | — | — | US | disclosed |
| US-20240366782-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2024-11-07 | — | — | US | disclosed |
| EP-4422695-A1 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | Araris Biotech AG (CH) | 2024-09-04 | — | — | EP | disclosed |
| US-12076412-B2 | Antibody-drug conjugates through specific linker oligopeptides | ARARIS BIOTECH AG (CH) | 2024-09-03 | — | — | US | disclosed |
| WO-2024129990-A2 | CHEMICALLY MODIFIED AAVS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-118159298-A | Method for producing antibody-linker conjugates | 阿拉里斯生物技术股份公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117750981-A | Peptides comprising N-formyl-halomethionine residues and engineered antibody-peptide conjugates thereof | 伊莱利利公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2022084560-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022058594-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2022-03-24 | — | — | WO | disclosed |
| EP-3941526-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | Paul Scherrer Institut (CH) | 2022-01-26 | — | — | EP | disclosed |
| CN-113966339-A | Conotoxin peptide analogs and uses for treating pain and inflammatory conditions | 奇尼塔慢性疼痛有限责任公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113613679-A | Transglutaminase conjugation methods for glycine-based linkers | 保罗·谢勒学院 | 2021-11-05 | — | — | CN | disclosed |
| US-20200363423-A1 | MISTRANSLATION METHOD FOR ASSESSING THE EFFECTS OF AMINO ACID SUBSTITUTIONS ON PROTEIN STABILITY AND FUNCTION | UNIVERSITY OF WASHINGTON (US) | 2020-11-19 | — | — | US | disclosed |
| WO-2020188061-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | PAUL SCHERRER INSTITUT (CH) | 2020-09-24 | — | — | WO | disclosed |
| US-20200237924-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | KINETA CHRONIC PAIN, LLC (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3553078-A1 | GLYCO-ENGINEERED INTERLEUKIN-4 BASED ANTAGONISTS | Julius-Maximilians-Universität Würzburg (DE) | 2019-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398972-A1 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | SP1, TGM1, KDM3A | GABRR1 3719/4885LMNA 1731/4885SLC22A6 1669/4885 |
| US-20200237924-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | CHRNG, CHRNA9, CHRNA10 | GABRR1 180/4885LMNA 1324/4885SLC22A6 4517/4885 |
| US-12076412-B2 | Antibody-drug conjugates through specific linker oligopeptides | TGM1, SP1, TGM3 | GABRR1 2276/4885LMNA 2436/4885SLC22A6 2194/4885 |
| US-20250049943-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | TGM1, TGM3, PRMT3 | GABRR1 2382/4885LMNA 3084/4885SLC22A6 2870/4885 |
| US-20240366782-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | TGM1, TGM3, PRMT3 | GABRR1 2382/4885LMNA 3084/4885SLC22A6 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.